Clinical trials: Sweat Gland Diseases
Hidradenitis Suppurativa
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
- Trial name
- NCT06768671
- Testing
- Sonelokimab
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa (HS)
Neutralizing Interferon Type 1 in Hidradenitis Suppurativa
The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer…
- Trial name
- NIHS-I (NCT07067099)
- Testing
- Plasma with neutralizing autoantibodies to Type I Interferons
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hidradenitis Suppurativa
Pathophysiological Basis of Hidradenitis Suppurativa
HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous…
- Trial name
- NCT06370052
- Testing
- excision
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Center Rijeka
Autonomic Nervous System Diseases, Sweat Gland Diseases
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
The purpose of this study is to conduct an interventional, one year, randomized, double blind, placebo-controlled trial with Liraglutide in patients with type 2 diabetes (diabetes duration of >6 months and <10 years, HbA1c <10%)…
- Conditions
- Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
- Trial name
- NCT03426085
- Testing
- Liraglutide 6 mg Solution for Injection
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Eastern Virginia Medical School
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NOVA (NCT03628924)
- Testing
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 184 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.
- Trial name
- NCT07855276
- Testing
- LOU064
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa
- Trial name
- NCT05348681
- Testing
- RIST4721
- Where
- 12 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Aristea Therapeutics, Inc.
Hidradenitis Suppurativa
Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa
This study is being conducted to evaluate if a written action plan for hidradenitis suppurativa (HS) will help patients with hidradenitis suppurativa gain a better understanding of the condition and how to manage the condition on…
- Trial name
- NCT04600375
- Testing
- Verbal consultation, Written Action Plan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
Hidradenitis Suppurativa
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions.
- Trial name
- Step-Up HS (NCT05889182)
- Testing
- Upadacitinib
- Where
- 285 sites in United States, Argentina and 35 more
- Volunteers
- 1,328 people
- Sponsor
- AbbVie
Acne, Bites
Implementation of a Minor Ailment Service in Community Pharmacy Practice
Self-care and self-medication are commonly the treatments of choice for the management of minor ailments. Minor ailments can be treated through community pharmacy using a Minor Ailment Service (MAS).
- Conditions
- Acne, Bites, Burns, Cold
- Trial name
- INDICA+PRO (NCT05247333)
- Testing
- Minor ailment service
- Where
- Spain
- Volunteers
- 20,987 people
- Sponsor
- Universidad de Granada
Hyperhidrosis
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
Hyperhidrosis is defined as excessive sweating and affects about 2.8 % of the population. It has been shown to have a deleterious effect on the quality of life measured using the Dermatology Life Quality Index (DLQI) which is one…
- Trial name
- NCT01930604
- Testing
- Botox (onabotulinumtoxinA), NeuroBloc/Myobloc (rimabotulinumtoxinB)
- Where
- Sweden
- Volunteers
- 588 people
- Sponsor
- Carl Swartling
Hidradenitis Suppurativa
LTX-109 as Treatment for Hidradenitis Suppurativa
An Open label Phase II//proof of concept-study to demonstrate if percutaneous application of LTX-109 in a gel vehicle is a safe treatment of Hidradenitis suppurativa and to identify clinical response to intervention, as well to…
- Trial name
- NCT04756336
- Testing
- LTX-109 gel, 3% w/w
- Where
- Norway
- Volunteers
- 11 people
- Sponsor
- Pharma Holdings AS
Hyperhidrosis
Assessing the Effect of Patient Characteristics on Treatment Response in Primary Hyperhidrosis
This study will describe the treatment of hyperhidrosis (excessive sweating) in clinical practice and explore the effect of patient characteristics on treatment response.
- Trial name
- NCT03694093
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Louis University
Cystic Fibrosis
(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?
Clinical studies of lumacaftor + ivacaftor (combo therapy) produced better FEV1 (forced expiratory volume in 1 second) improvements than ivacaftor alone, without further improvement in sweat chloride results.
- Trial name
- NCT02310789
- Testing
- Ivacaftor, β-Adrenergic cocktail, Pilocarpine Nitrate 5%
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Richard Barry Moss
Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of…
- Trial name
- NCT06932003
- Testing
- LT-002-158 Tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Hidradenitis Suppurativa
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD).
- Trial name
- NCT06058520
- Testing
- Fecal Microbiota - lyophilized
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Minnesota
ROSAH Syndrome, Anhidrosis
A Method Characterization Study to Evaluate Thermoregulatory Sweat Production in Healthy Volunteers and Patients With ROSAH Syndrome)
This study is designed to characterize a new quantitative method for measuring sweat production induced by controlled heat exposure. Approximately 20 healthy volunteers and up to 10 patients with ROSAH syndrome will be enrolled.
- Conditions
- ROSAH Syndrome, Anhidrosis, Hypohidrosis
- Trial name
- NCT07814209
- Testing
- Standardized Controlled Heat Exposure With Gravimetric Sweat Collection
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c.
- Conditions
- Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
- Trial name
- NCT07261072
- Testing
- Topical injection of Secukinmab, Subcutaneous injection of Secukinumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Hidradenitis Suppurativa (HS)
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS).
- Trial name
- NCT07109765
- Testing
- Secukinumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College